Sling Therapeutics is advancing the first late-stage oral drug for thyroid eye disease that, if approved, could compete ...

The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday ...

A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving ...

Biopharma professionals are among those delaying retirement, with 52% expecting to leave the workforce later than originally ...

As AI becomes more embedded in biotech R&D, companies are competing for professionals who can bridge biology, machine ...

Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit compliance in ...

A study published today in JAMA Network Open, led by anesthesiologists at Montefiore Einstein, demonstrates that reducing IV ...

The National Organization for Rare Disorders (NORD®) and the Rosenau Family Research Foundation today launched Rare Research ...

Study assessments include measurements of mutant HTT protein, PMS1 mRNA, and cUHDRS. Enrollment and treatment in the Phase ...

Nonclinical bridging data further support the pharmacologic activity of the recalibrated dose. In a Danon disease mouse model ...

Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program ...

(GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development ...